A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies

NCT00807677 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

31

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Chronic Myelogenous Leukemia
Chronic Lymphocytic Leukemia
Multiple Myeloma
Waldenstrom's Macroglobulinemia
Myelodysplastic Syndrome
Philadelphia Chromosome-negative CML
Myeloid Metaplasia
Myelofibrosis
Advanced Polycythemia
Non-Hodgkins Lymphoma

Interventions

DRUG: TAK-901

Sponsor

Millennium Pharmaceuticals, Inc.